Jose Loyo Molina, MD
Interventional Cardiology · Fort Smith, ARNPI 1134314511
Payments from drug & device makers
Across 462 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Boston Scientific$947
- Amarin Pharma, Inc.$832
- Amgen$719
- Merck$692
- Abiomed$515
- plus $3K from 27 others
What the payments were for
- Food & beverage$8,49699%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 93 | $1,499 |
| Boston Scientific | 45 | $947 |
| Amarin Pharma, Inc. | 46 | $832 |
| Amgen | 38 | $719 |
| Merck | 42 | $692 |
| Abiomed | 4 | $515 |
| Boehringer Ingelheim | 23 | $402 |
| Johnson & Johnson | 24 | $394 |
| AstraZeneca | 26 | $383 |
| Bayer | 24 | $371 |
| Medtronic | 8 | $358 |
| Sanofi-aventis U.S. LLC | 19 | $329 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $219 |
| Astellas Pharma US Inc | 4 | $140 |
| E.r. Squibb & Sons, L.L.C. | 7 | $102 |
| Esperion Therapeutics, Inc. | 8 | $98 |
| Regeneron Healthcare Solutions, Inc. | 6 | $92 |
| Cardiovascular Systems Inc. | 1 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $73 |
| Novo Nordisk | 4 | $65 |
| Pfizer | 4 | $51 |
| Philips North America LLC | 2 | $43 |
| Lexicon Pharmaceuticals, Inc. | 2 | $29 |
| Gilead | 2 | $23 |
| Eisai Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Abbott | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$493
- COBALT DR MRI SURESCAN$130
- Repatha$125
- Cobalt$120
How this compares
$8,586 in reported general payments places this provider in the 55th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 202 | $160,340 |
| EntrestoSacubitril/Valsartan | 117 | $92,698 |
| JardianceEmpagliflozin | 70 | $60,792 |
| XareltoRivaroxaban | 50 | $45,917 |
| Ranolazine ErRanolazine | 356 | $17,215 |
| BrilintaTicagrelor | 30 | $17,136 |
| VerquvoVericiguat | 19 | $16,937 |
| FarxigaDapagliflozin Propanediol | 23 | $16,231 |
| Amlodipine Besylate | 663 | $2,325 |
| Isosorbide Dinitrate | 62 | $2,209 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 328 | $2,195 |
| Irbesartan | 134 | $2,098 |
| Potassium Chloride | 222 | $2,045 |
| Atorvastatin Calcium | 346 | $1,845 |
| Carvedilol | 455 | $1,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $51 | $160,340202 claims |
| NovartisEntresto | $1,499 | $92,698117 claims |
| Boehringer IngelheimJardiance | $402 | $60,79270 claims |
| Johnson & JohnsonXarelto | $394 | $45,91750 claims |
| AstraZenecaBrilinta, Farxiga | $383 | $33,36753 claims |
| MerckVerquvo | $692 | $16,93719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Fort Smith
- Rudhir TandonFort Smith$22K
- Hussam HawamdehFort Smith$16K
- Pooja MishraFort Smith$10K
- Gaurav DharLittle Rock$793K
- Ernesto Ruiz-RodriguezLittle Rock$499K
- Joel CarverFayetteville$305K
- Vasili LendelLittle Rock$206K
- Vijay RajaLittle Rock$106K
- Thomas WattsLittle Rock$79K
- Lena AwarJonesboro$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.